Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2000

View Archived Issues

Aurora acquires Quorum Sciences

Antex licenses lantibiotics with promise for antibiotic-resistant bacteria

Complete analysis of data from Neotrofin phase II trial

Vertex expands product pipeline

Posaconazole active against histoplasmosis in immunocompromised animals

Cryptococcus neoformans potently inhibited by ravuconazole in recent in vitro study

ABT-773 effective against disseminated MAC infection in vivo

Pharmacokinetics, disposition and metabolism of new hepatic antiinflammatory TA-510

Chemotherapeutic potential of competitive glyoxalase I inhibitor evaluated in tumor-bearing mice

E-6060, a potential new therapy for antibody-dependent autoimmune diseases

Vivus begins patient enrollment for female sexual dysfunction trial

Antisoma licenses thioplatin from German cancer center

Immunotherapy with beta-alethine useful in minimal residual disease

Safe new agents from Ajinomoto with potential in irritable bowel syndrome

Substituted aza-oxindoles which inhibit protein tyrosine or serine/threonine kinases

Patient enrollment begins in phase I trial of Cotara for colorectal cancer

Novo Nordisk's new potassium channel openers specifically claimed for diabetes

Inflammatory cytokine-reducing compounds designed at Celgene

Novel GH secretagogues claimed by BMS

Boehringer Ingelheim presents new series of inhibitors of signal transduction

Subtype-selective estrogen receptor modulators described by Signal, AxyS

BioChem Pharma to acquire CliniChem

Zevalin effective and safe in refractory, heavily pretreated NHL patients

License to new drug delivery technology obtained by Kos

Melacine as adjuvant therapy in melanoma: phase III data reported at SBT meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...